Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Pacira BioSciences, Inc. (PCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors"
09/26/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TRANSITION AND RETIREMENT AGREEMENT",
"Pacira BioSciences Announces Leadership Succession Plan David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor"
08/02/2023 8-K Quarterly results
05/03/2023 8-K Quarterly results
Docs: "Pacira BioSciences Reports First Quarter 2023 Financial Results"
04/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "CREDIT AGREEMENT",
"Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources"
03/22/2023 8-K Quarterly results
02/28/2023 8-K Quarterly results
Docs: "Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results — Record revenues of $667 million in 2022"
01/05/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million"
12/13/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/13/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million"
09/13/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022"
08/10/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Pacira BioSciences Reports Second Quarter 2022 Financial Results"
07/14/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/12/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022 – EXPAREL achieved record net product sales of $51.2 million for month of March with average daily sales at 116% of the prior year –"
03/15/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022"
02/24/2022 8-K Quarterly results
02/15/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022"
02/07/2022 8-K/A Quarterly results
01/06/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira Reports Preliminary Unaudited Total Revenue for 2021 of of $540.7 Million to $541.7 Million"
12/09/2021 8-K Quarterly results
12/07/2021 8-K Quarterly results
11/19/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "Agreement”), is entered into by and between Pacira BioSciences, Inc., a Delaware corporation , and American Stock Transfer & Trust Company, LLC, a New York limited liability company, as Rights Agent (the “Rights Agent",
"Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management"
11/09/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021"
11/03/2021 8-K Quarterly results
Docs: "Pacira BioSciences Reports Third Quarter 2021 Financial Results"
10/12/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financia...
Docs: "AGREEMENT AND PLAN OF MERGER by and among: FLEXION THERAPEUTICS, INC., PACIRA BIOSCIENCES, INC., and OYSTER ACQUISITION COMPANY INC.",
"TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement is entered into as of October 11, 2021, by and among Pacira BioSciences, Inc., a Delaware corporation , Oyster Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent , and [●] . Recitals A. Stockholder is a holder of record and the “beneficial owner” ) of certain shares of common stock of Flexion Therapeutics, Inc., a Delaware corporation . B. Parent, Purchaser and the Company are entering into an Agreement and Plan of Merger dated on or about the date hereof which provides, among other things, for Purchaser to commence a cash tender offer to acquire all of the outstanding shares of Company Common Stock, par value $0.001 per share, of the Company and following the consummation of the Offe...",
"Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management",
"Pacira to Acquire Flexion, Further Expanding Leadership Position in Non-Opioid Pain Management October 11, 2021",
"Pacira BioSciences Corporate Speakers: · Susan Mesco; Pacira BioSciences, Inc.; Head of IR · David Stack; Pacira BioSciences, Inc.; Chairman & CEO · Ronald Ellis; Pacira BioSciences, Inc.; SVP · Charles Reinhart; Pacira BioSciences, Inc.; CFO Participants:",
"Forward-Looking Statements Any statements in this communication about Pacira’ s or Flexion’ s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements related to the anticipated consummation of the acquisition of Flexion and the timing and benefits thereof, Pacira’ s strategy, plans, objectives, expectations and intentions, future financial results and growth potential, anticipated product portfolio, development progr..."
09/15/2021 8-K Quarterly results
08/10/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy